CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
Globe Newswire•29/09/2026•07:00 ET
0
Key Highlights
- ➤Sarborg filing expands quantum computing IP into disease biology and drug discovery
- ➤CDT (CDT) holds 1,290 Sarborg shares, representing 22.7% of issued share capital
- ➤Sarborg capital raise at $125,000 per share implied approximately $709 million valuation
- ➤Model applied across 150 disease networks, including Crohn's disease, COPD and psoriasis
- ➤Sarborg in discussions with a leading global quantum computing company on hardware partnership
Expert Statements
Dr. Andrew Regan, Chief Executive Officer of Sarborg
“Much of the quantum sector is still looking for problems that genuinely suit the hardware. We started from one.”
Dr. Andrew Regan, Chief Executive Officer of Sarborg
“Disease genes are controlled by committees of regulators acting together, a combinatorial layer conventional methods miss, and quantum samplers are built to explore. Our model delivers druggable, genetically supported targets today and is ready for quantum hardware by design. Our discussions with a leading quantum computing company to implement it in hardware are advancing strongly.”
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement from Sarborg Limited regarding the filing of new intellectual property applying quantum sampling to disease biology and drug discovery. CDT holds 1,290 shares in Sarborg, representing 22.7% of the issued share capital. Sarborg’s latest capital raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million.
A copy of Sarborg’s full announcement is available below and at www.sarborg.com/news.
Get started
Create a free account to read the full story.